Navegando por Autor "PEDROZA, Larysse Santa Rosa de Aquino"

Agora exibindo 1 - 1 de 1

Acesso aberto (Open Access)
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil
(2013) VASCONCELOS, Janaina Mota de; MÓIA, Lizomar de Jesus Maués Pereira; AMARAL, Ivanete do Socorro Abraçado; MIRANDA, Esther Castello Branco Mello; TAKESHITA, Louise Yukari; OLIVEIRA, Layanna Freitas de; MENDES, Lilian de Araújo Melo; SASTRE, Danuta; TAMEGÃO-LOPES, Bruna Pedroso; PEDROZA, Larysse Santa Rosa de Aquino; SANTOS, Sidney Emanuel Batista dos; SOARES, Manoel do Carmo Pereira; ARAÚJO, Marialva Tereza Ferreira de; BANDEIRA, Camila Lucas; SILVA, Adriana Maria Paixão de Sousa da; MEDEIROS, Zilene Lameira de; SENA, Leonardo dos Santos; DEMACHKI, Sâmia; SANTOS, Eduardo José Melo dos
Soroprevalence for Hepatitis C virus is reported as 2.12% in Northern Brazil, with about 50% of the patients exhibiting a sustained virological response (SVR). Aiming to associate polymorphisms in Killer Cell Immunoglobulin-like Receptors (KIR) with chronic hepatitis C and therapy responses we investigated 125 chronic patients and 345 controls. Additionally, 48 ancestry markers were genotyped to control for population stratification. The frequency of the KIR2DL2 and KIR2DL2+HLA-CAsp80 gene and ligand was higher in chronic infected patients than in controls (p < 0.0009, OR = 3.4; p = 0.001, OR = 3.45). In fact, KIR2DL3 is a weaker inhibitor of NK activity than KIR2DL2, which could explain the association of KIR2DL2 with chronic infection. Moreover, KIR2DS2 and KIR2DS2+HLA-CAsp80 (p < 0.0001, OR = 2.51; p = 0.0084, OR = 2.62) and KIR2DS3 (p < 0.0001; OR = 2.57) were associated with chronic infection, independently from KIR2DL2. No differences in ancestry composition were observed between control and patients, even with respect to therapy response groups. The allelic profile KIR2DL2/KIR2DS2/KIR2DS3 was associated with the chronic hepatitis C (p < 0.0001; OR = 3). Furthermore, the patients also showed a higher mean number of activating genes and a lower frequency of the homozygous AA profile, which is likely secondary to the association with non-AA and/or activating genes. In addition, the KIR2DS5 allele was associated with SVR (p = 0.0261; OR = 0.184).The ancestry analysis of samples ruled out any effects of population substructuring and did not evidence interethnic differences in therapy response, as suggested in previous studies.